Kornimate/medical-research-clean huggingface dataset:
emergency room hpv self-sampling study (act now)

Conditions: Cervical Cancer Screening

Summary: the goal of this study is to develop and evaluate an evidence-based public health intervention using hpv self-sampling approach in an opportunistic setting to increase cervical cancer screening among screening non-attendees, particularly those uninsured or underinsured, who use emergency services to access medical care. the proposed pilot study will examine the feasibility and efficacy of hpv self-sampling among women at a safety net hospital emergency room. participant recruitment and self-sample will take place in the waiting rooms in the er. all women sitting in the waiting room will serve as the source population for the study and will be approached and invited to participate in the study.


Eligibility criteria:
inclusion criteria: * eligible participants are women ages 25 years to 65 years, with a cervix, presenting in the waiting areas at the ben taub general hospital emergency department exclusion criteria: * women under 25 years or older than 65 years of age, * self-reported current pregnancy, * self-reported history of cervical cancer, * past hysterectomy, * had pap smear within past 3 years or hpv/pap co-test within past 5 years.
latest imaging spect system evaluation phase 1

Conditions: Rheumatic Disease; Neoplasms; Parathyroid Diseases; Pulmonary Embolism; Heart Diseases; Thyroid Diseases; Kidney Diseases; Dementia; Parkinsonian Disorders

Summary: monocentric study for the evaluation of a whole body czt scintigraphy system.

monocentric evaluation of performances and clinical interest of a whole body scintigraphic acquisition system with czt digital detectors. comparison of image quality and resolution of the new system compared to a reference one, on phantoms and during the acquisition of a wide variety of examinations.

Eligibility criteria:
inclusion criteria: * patients referred to our nuclear medicine department for bone, cardiac, pulmonary, thyroid, parathyroid, renal or cerebral perfusion scintigraphy or to datscan. exclusion criteria: * under 18 years old patients. * pregnant women or at risk of pregnancy. * patients under guardianship * painful patient (eva\>4) * patients in whom a standard examination is not feasible (agitation).

Keywords: gamma camera whole body scan scintigraphy
comparison of the efficacy for stress ulcer prophylaxis between the patients received lansoprazole od and control group weaning from mechanical ventilator in respiratory care center: a randomized control trial

Conditions: Respiratory Failure

Summary: the purpose of this study is to determine whether lansoprazole administered nasogastrically is effective for stress ulcer prophylaxis in respiratory intensive care unit.

although stress ulcer is a complication that can cause mortality and morbidity in critical patients, there is still lack of consensus about its prophylaxis. there is also few data available from taiwan. h2 blockers are commonly used due to convenience. some prefer sucralfate (a mucosal protective agent) for the sake of less associated nosocomial pneumonia. recently, proton pump inhibitors were shown to have good prophylactic effects for stress ulcer. lansoprazole has good acid suppression effect and the tablets are soluble for the use of tube feeding. there was no data about the prophylaxis of stress ulcer development during the program of weaning from the mechanical ventilators. therefore, we conduct a study of the comparison of lansoprazole administered nasogastrically and control group for stress ulcer prophylaxis in respiratory intensive care unit.

Eligibility criteria:
inclusion criteria: 1. initial icu admission, apache ii score ≥25。 2. evidence of iicp ( icp monitor proved or brain ct proved edema)。 3. evidence of peptic ulcer disease ( a or h) proved by pes more than 3 months ago without ppi or h2 blocker agents therapy in recent one week。 4. ugi bleeding history in icu before transferring to rcc (proved by ng aspirate coffee ground substance or fresh blood ≥ 60 ml)。not received ppi or h2 blocker agents in recent one week. 5. received nsaid for more than 7 days。 6. bleeding tendency or with major disease patients: coagulopathy, esrd (ccr\<10), hematologic malignancy, liver cirrhosis child c。 exclusion criteria: 1. age \< 18 y/o, pregnancy。 2. active ugi bleeding and under ppi or h2-blockers。 3. family unwillings。

Keywords: lansoprazole, weaning,stress ulcer prophylaxis
neurodevelopmental outcomes and fluconazole prophylaxis

Conditions: Neurodevelopmental Outcomes

Summary: the purpose of this study is to compare the neurodevelopmental outcome and quality of life between the fluconazole-treated and the placebo-treated patients that were enrolled in a fluconazole prophylaxis study that occurred in the investigators' neonatal intensive care unit (nicu) between 1998-2000.

invasive fungal infections in preterm infants is associated with significant morbidity and mortality. mortality in infected infants \< 1000 grams is between 26-66% and neurodevelopmental impairment occurs in 57%.1-13 between 1998-2000 we conducted a randomized placebo controlled trial of fluconazole prophylaxis in 100 infants \<1000 grams at birth(irb-hsr #9389). invasive fungal infections occurred in none of the fluconazole-treated patients compared to 20% of the placebo group. following this study the efficacy has been confirmed in a multicenter randomized controlled trial and 7 retrospective studies. one major issue that has remained is whether the fluconazole-treated infants have better neurodevelopmental outcomes as well as if it is safe without an increase in neurodevelopmental impairment. neurodevelopmental outcomes can be assessed by testing and examinations or by parental and child questionnaires. in addition, quality of life is an important context of outcomes. recent conceptualizations of quality of life recognize the multidimensional nature of quality of life, including psychological and social functioning, consistent with the world health organization's definition of health as "not only the absence of disease and infirmity, but the presence of physical, mental, and social well-being." the world health organization subsequently emphasized the growing consensus that quality of life is a subjective experience, defined as "individuals' perceptions of their position in life in the context of the culture and value systems in which they live, and in relation to their goals, expectations, standards, and concerns." to address these issues, we aim to study and compare the neurodevelopmental outcome and quality of life between our fluconazole-treated and placebo-treated patients in our initial study

Eligibility criteria:
inclusion criteria: * parents or guardians and their infants who survived and were enrolled in our initial study of fluconazole prophylaxis for prevention of fungal colonization and infection in preterm infants \< 1000 grams exclusion criteria: * persons not meeting the inclusion criteria

Keywords: fluconazole prophylaxis fungal colonization fungal infection preterm infants long term outcomes quality of life
assessment of sars-cov-2 effect on post-traumatic stress of patients hospitalized in intensive care unit

Conditions: Intensive Care Unit; SARS-CoV2

Summary: patients admitted to the intensive care unit develop psychiatric disorders, such as anxiety, depression or post-traumatic stress disorder, which can be prolonged. during the covid crisis, the presence of relatives in the intensive care unit was reduced and this, in a lasting way. the hypothesis is that there is a difference in the experience of the stay in the intensive care unit whether or not one is affected by sars-cov-2 and that this difference is likely to have an impact on the long-term outcome of the patients and their relatives.

the stay in the icu is a complex and often traumatic experience for patients. patients often develop psychiatric disorders such as anxiety, depression or post-traumatic stress disorder after an icu stay. these symptoms can be prolonged over time, resulting in a decrease in quality of life and a potential cost in care. in the epidemic context of the covid crisis, the presence of family members in the intensive care unit was reduced to its most extreme portion, with sometimes an almost total impossibility of visiting a loved one. this situation, although it has become less strict, has lasted for a long time. the patient can only exchange with them with difficulty, despite the extremely trying situation that is resuscitation. moreover, there is a stress factor linked to the infectious risk for the relatives and for the relatives with regard to covid-19, in particular within the framework of family clusters with sometimes several hospitalized subjects within the same family. of course, means of communication have been put in place with relatives, but these means do not seem to be equivalent to the presence of one's relatives. the investigators therefore hypothesize that there is a difference in the experience of the stay in the intensive care unit whether or not one is affected by sars-cov-2 and that this difference is likely to have an impact on the long-term outcome of patients and their relatives.

Eligibility criteria:
inclusion criteria: * major patients (above 18 years old) * admitted in intensive care unit * hospitalized more than 2 days (48 hours) * between 01/01/2020 and 06/30/2020 * whether sars-cov-2 positive or negative exclusion criteria: * minor patient * protected major (under safeguardship, curatorship or guardianship) * patient opposition

Keywords: sars-cov-2 post-traumatic stress anxiety depression covid-19 intensive-care
exercise for depressed smokers

Conditions: Tobacco Smoking; Smoking Cessation

Summary: the purpose of this study is to test the effect of a moderate-intensity aerobic exercise intervention for helping individuals with elevated depressive symptoms to quit smoking. the investigators expect that this project will contribute much needed knowledge about the role that aerobic exercise can play in smoking cessation. the long-term goal of this program of research is to disseminate an effective, aerobic exercise (ae) intervention for smoking cessation that can be readily adopted by smokers with elevated depressive symptoms, including those with current major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: 1. are between 18 and 65 years of age 2. are current smokers (i.e., smoking at least 10 cigarettes per day) 3. have currently elevated depressive symptoms (ces-d ≥ 6) 4. are sedentary, i.e., have not participated regularly in aerobic exercise (for at least 90 minutes per week during the past three months) exclusion criteria: 1. dsm-iv diagnosis of current mania 2. dsm-iv diagnosis of bipolar rapid cycling 3. lifetime history of psychotic disorder or dsm-iv diagnosis of current psychotic symptoms 4. dsm-iv diagnosis of current substance abuse or dependence in the past 6 months 5. dsm-iv diagnosis of anorexia or bulimia nervosa 6. current suicidality or homicidality 7. marked organic impairment 8. current use of antidepressant medication for less than 3 months or change in antidepressant medication or dosage in the past 3 months, 9. physical disabilities or medical problems that would prevent or hinder participation in a program of moderate intensity exercise (i.e., physician denied medical clearance) 10. current pregnancy or intent to become pregnant during the next 12 weeks 11. contraindications for use of the nicotine patch (e.g., pregnancy, recent myocardial infarction, arrhythmia, angina, untreated hypertension, untreated diabetes, and previous adverse reaction to the patch) 12. current illness or medications that may alter proposed inflammatory markers (e.g., acute infection, immune disorders, aspirin) 13. current use of any pharmacotherapy or other treatment for smoking cessation.

Keywords: quit smoking exercise tobacco smoking
study to investigate the safety, tolerability and efficacy of yh4808 in patients with reflux esophagitis

Conditions: Reflux Esophagitis

Summary: this study is to investigate the optimal clinical dose and administration methods of yh4808 in patients with reflux esophagitis by evaluating the safety and efficacy after yh4808 oral administration.

in the result of recent meta-analysis, there was no improvement in symptoms with the first administration of ppi in about 75% of gerd patients, and symptoms were still sustained in about 50% of patients after administration of more than 3 days. especially the nocturnal secretion of gastric acid was not effectively inhibited, and about 25% of gerd patients could not achieve the proper therapeutic effects even after ppi treatment twice daily for 4-8 weeks. yh4808, as a selective k+- competitive acid blocker (p-cab), is no need for activation by gastric acid since it competitively inhibits proton pump with k+. thus, the inhibition of gastric acid secretion by yh4808 is prompt and effective. in addition, the inhibitive effect of gastric acid secretion by stimulation of histamine is proved to be more powerful than ppi (esomeprazole) and sustained in in-vitro/in-vivo model, and 24-h inhibition of gastric acid secretion and especially nocturnal inhibition of gastric acid secretion was observed to be superior to esomeprazole with repeat doses for 7 days in healthy volunteers. based on these nonclinical and clinical outcomes, an exploratory phase-ii clinical trial is to be conducted to determine the proper treatment dose and administration method of yh48084 for gerd patients.

Eligibility criteria:
inclusion criteria: 1. subject who has signed on the written consent 2. male and female aged 20 and over 3. endoscopically verified reflux esophagitis classified into los angeles classification grade a, b, c or d within 2 weeks before randomisation exclusion criteria: 1. history or presence of upper gastrointestinal anatomic or motor disorders 2. other exclusions apply.
high resolution ultrasound of scapulae alatae - a prospective case control study

Conditions: Scapula Alata; Scapular Winging

Summary: scapula alata, caused by disturbance in the scapulothoracic stabilizer muscles due to nerve injury, is a relatively rare but also underreported disease. it can lead to years of invalidity of the affected upper extremity, considerable pain and social and emotional consequences for the patients. unrecognized and misdiagnosed scapula alata and, consequently, wrong or delayed treatment is a general problem in this patient group. today the diagnosis is based on the clinical examination and the electrophysiological examination. one of the problems is that the electrophysiological examination in a fair part of the patients is not showing any pathology even though the history of the patient and the clinical evaluation are indicating scapula alata. this study is a single-blinded, prospective, controlled multicentre study. the aim of the study is to investigate whether ultrasound can be used as a supplement to the electrophysiological examination when diagnosing scapula alata. ultrasound will be used to visualize possible thickening of the cross-sectional area of nerves and the degree and pattern of muscle involvement in patients with scapula alata. by comparing measurements from scapula alata patients with the measurements from healthy controls, we are able to see if ultrasound can distinguish these two groups from each other. furthermore, we will examine whether the ultrasound measurements correlate with the electrophysiological findings in patients and, when available, compare the ultrasound measurements of muscle thickness with mri (magnetic resonance imaging) findings. the use of ultrasound in scapula alata patients may help determine the presence and severity of a nerve lesion and the subsequent degree of muscle involvement and may therefore serve as a supplement to the clinical diagnosis.


Eligibility criteria:
patients: inclusion criteria: * clinical suspicion of scapula alata exclusion criteria: * winged scapula due to other cause than nerve damage. eg. myopathy healthy subjects exclusion criteria: * history of shoulder trauma or shoulder disease * history of cervical radiculopathy * history of upper extremity peripheral neuropathy/plexopathy * peripheral vascular disease

Keywords: scapula/innervation* thoracic nerves/injuries* peripheral nerve injuries shoulder musculoskeletal diseases/diagnosis*
clinical efficacy and safety evaluation of hcp1904-2 in essential hypertension patients

Conditions: Hypertension

Summary: the purpose of this study is to evaluate of efficacy and safety of hcp1904-2 and rld2001-2 alone in patients with essential hypertension inadequately controlled on rld2001-2 monotherapy.

a multi-center, randomized, double-blinded, active-controlled, parallel, phse iii study to evaluate the efficacy and safety of hcp1904-2 in essential hypertension patients

Eligibility criteria:
inclusion criteria: 1. patients over 18 years of age 2. patients who understands the process of clinical study and voluntarily signs a peer letter 3. visit1: a person whose blood pressure measured in visit1 corresponds to the following conditions * blood pressure medication taken patients: 130mmhg ≤ sitsbp\<180mmhg, sitdbp\<110mmhg * blood pressure medication free patients: 140mmhg ≤ sitsbp\<180mmhg, sitdbp\<110mmhg 4. visit2: 140mmhg ≤ sitsbp\<180mmhg, sitdbp\<110mmhg or if patients are in high risk group: 130mmhg ≤ sitsbp \<180mmhg, sit dbp \< 110mmhg exclusion criteria: * difference in mean value of blood pressure measured in both arms of more than 20mmhg in sitsbp or more than 10mmhg in sitdbp * orthostatic hypotension with symptoms within 3months of visit 1 * secondary hypertensive patient or suspected to be * uncontrolled diabetes mellitus(hba1c \> 9%) or type i diabetes mellitus * active gout or hyperuricemia (uric acid ≥ 9mg/dl) * severe heart disease or severe neurovascular disease * severe or malignant retinopathy * clinically significant hematological finding * severe renal diseases (egfr\<30ml/min/1.73m2) * severe hepatopathy or active hepatopathy (ast or alt normal range ≥ 3 times) * hypokalemia or hyperkalemia(k\<3.5mmol/l or k ≥ 5.5mmol/l) * hyponatremia or hypernatremia(na\<135mmol/l or na ≥ 155mmol/l) * hypercalcemia * history of malignancy tumor * history of autoimmune disease * history of alcohol or drug abuse * positive to pregnancy test, nursing mother, intention on pregnancy * considered by investigator as not appropriate to participate in the clinical study with othe reason

Keywords: losartan chlorthalidone
effectiveness of distracted driving campaign

Conditions: Trauma Prevention

Summary: the study will measure the effectiveness of a distracted driving campaign in the emergency department in teenagers, 15 to 18 years old, to determine if it changes their attitudes towards texting while driving. it will also assess previous knowledge and behaviors in this age group, regarding distracted driving and what educational tool (power point vs. videos vs. brochure) has the most impact changing the attitudes towards texting and driving.

distracted driving is defined by the national highway safety administration (nhtsa) as any activity that could withdraw a person's attention away from the primary task of driving. it includes, talking or texting on a cell phone, grooming, eating or drinking, changing radio stations, or talking to passengers. of all these activities text messaging is by far the most alarming distraction because it requires visual, manual, and cognitive attention from the driver. the nhtsa research note on distracted driving found that in 2011, 10% percent of fatal crashes were reported as distraction-affected crashes. this research also showed that teens between 15 to 19 years old are currently the largest group with distracted driving affected crashes, with 21% percent of them getting distracted while using their cell phones. during the last few years, multiple public awareness campaigns have been launched in attempt to reduce this problem. these massive campaigns have included television, radio and internet campaigns, posters, billboards and brochures among others. nevertheless, there are no studies assessing the success of these methods. the research project will use visual and verbal educational tools to engage this population in order to maximize the learning process. the project will include brochures, video presentations and power point presentations. the investigators intend to test a potentially new and effective way to teach our teenagers about the dangers of distracted driving. the project primary goal is to assess if a distracting driving campaign in the emergency department is effective in changing the attitudes towards texting while driving. the investigator also intends to assess the current knowledge about distracted driving and to determine which tool (visual vs. verbal) is most effective to deliver this message.

Eligibility criteria:
inclusion criteria: * adolescents between the ages of 15 to 18 years exclusion criteria: * adolescents refusing to participate in the distracted driving campaign. * adolescents visiting the emergency department with a chief complaint related to mental illness, suicide ideation or attempt, or any complaint limiting the ability to complete the questionnaire. * adolescents with diagnosis of developmental delay that could affect his or her ability to complete the questionnaire. * adolescents that do not speak english (the videos about real people who have had accidents while texting and driving found at http://www.distraction.gov/faces/index.html are available only in english.

Keywords: texting and driving teenager and driving distracted driving campaign